Augustine Therapeutics announces 17 million euros Series A1 financing round.
Augustine Therapeutics, a pioneering biotech company from Leuven focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised 17 million euros in the first closing of its Series A round.
The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the US-based Charcot-Marie-Tooth Research Foundation. Current investors AdBio partners, V-Bio Ventures, PMV, VIB and Gemma Frisius Fund also joined the round.
Augustine Therapeutics was founded in 2019 and a spin-off company of VIB-KU Leuven. The company is developing best-in-class, novel, potent and subtype-selective small-molecule inhibitors of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, a class II histone deacetylase. HDAC6 is a well-known molecular target with strong biological rationale for neurological disorders and high therapeutic potential in cardiometabolic disease.
